Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 18Neoplasm Metastasis 10Triple Negative Breast Neoplasms 9Lung Neoplasms 9Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Endometrial Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 3Adenocarcinoma 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Vulvar Neoplasms 1Vomiting 1Uterine Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cystic Neoplasm 1Pancreatic Adenocarcinoma Metastatic 1

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Inoperable Locally Advanced HER2-Negative Breast Cancer × Taxes × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡